

Biomica CEO Set to Attend JP Morgan Healthcare Week in San Francisco, January 8-11, 2024

Rehovot, Israel – December 21, 2023 – Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of **Evogene Ltd.** (Nasdaq: EVGN) (TASE: EVGN), is gearing up for participation in the JP Morgan 42nd Annual Healthcare Week, scheduled to run from January 8 to 11, 2024, in San Francisco. Biomica will also be taking part in the Biotech Showcase conference.

Dr. Elran Haber, CEO of Biomica, will be available for one-on-one meetings throughout the week, starting on Monday, January 8, and concluding on Thursday, January 11, 2024. Those interested in scheduling a meeting with Dr. Haber can reach out to Biomica's investor or public relations team.

About Biomica Ltd.:

Biomica is a clinical stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing PRISM system, a proprietary computational platform powered by Evogene's MicroBoost AI tech-engine. licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN).

For more information, please visit www.biomicamed.com.

About Evogene Ltd.:

Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - *MicroBoost AI*, *ChemPass AI* and *GeneRator AI* – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each tech-engine is focused on the discovery and development of



products based on one of the following core components: microbes (*MicroBoost AI*), small molecules (*ChemPass AI*), and genetic elements (*GeneRator AI*).

Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene's subsidiaries currently utilize the tech-engines to develop human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio, ag-chemicals by AgPlenus, medical cannabis products by Canonic and castor varieties, for the biofuel and other industries, by Casterra.

For more information, please visit: www.evogene.com.

Contacts

Rachel Pomerantz Gerber

Head of Investor Relations at Evogene

rachel.pomerantz@evogene.com

Tel: +972-8-9311901